Ugonabo Onyinye, Turki M'hamed, Stewart Dane, Sherif Ahmed, Villa Xavier
Department of Internal Medicine, Marshall University, Joan C. Edwards School of Medicine, Huntington, WV, USA.
Division of Gastroenterology, Marshall University, Joan C. Edwards School of Medicine, Huntington, WV, USA.
Crohns Colitis 360. 2023 Jul 31;5(3):otad041. doi: 10.1093/crocol/otad041. eCollection 2023 Jul.
The inflammation and repair of the intestinal mucosa in inflammatory bowel disease (IBD) involve a complex interplay between innate, adaptive immune responses, and hormones. This may explain the relapsing clinical course of the disease.
We present the first reported case of a patient presenting their initial flare of ulcerative colitis immediately after discontinuing growth hormone (GH) therapy, suggesting treatment with GH or growth factors may prevent the development of IBD.
This is a case of a 13-year-old female with a history of GH deficiency, presenting with an 8-week history of abdominal pain, blood-stained diarrhea, and fecal calprotectin greater than 8000 mcg/g, 2 weeks after discontinuing GH therapy. The patient subsequently underwent an esophagoduodenoscopy and colonoscopy with biopsies showing histological features consistent with ulcerative colitis.
The finding of withdrawing GH or growth factors therapy potentially unmasking IBD in this patient raises a question of whether growth factors can inhibit the development of IBD and suggests beneficial effects of treatment with GH or growth factors as adjuvant therapy for IBD.
炎症性肠病（IBD）中肠黏膜的炎症和修复涉及先天免疫、适应性免疫反应和激素之间复杂的相互作用。这可能解释了该疾病复发的临床病程。
我们报告了首例在停用生长激素（GH）治疗后立即出现溃疡性结肠炎首次发作的患者，提示用GH或生长因子治疗可能预防IBD的发生。
这是一名13岁女性，有GH缺乏病史，在停用GH治疗2周后，出现腹痛、血便性腹泻8周病史，粪便钙卫蛋白大于8000 mcg/g。患者随后接受了食管十二指肠镜检查和结肠镜检查及活检，显示组织学特征符合溃疡性结肠炎。
该患者停用GH或生长因子治疗后可能暴露IBD这一发现，引发了生长因子是否能抑制IBD发生的问题，并提示用GH或生长因子治疗作为IBD辅助治疗的有益效果。
